Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Retatrutide (RETA) is a metabolic peptide, at the phase 3 trials stage in the published literature. Triple agonist targeting GIP, GLP-1, and glucagon receptors. Showing unprecedented weight loss in clinical trials.
Triple agonist targeting GIP, GLP-1, and glucagon receptors. Showing unprecedented weight loss in clinical trials.
| Research Status | Phase 3 trials |
|---|---|
| Half-Life | ~6 days |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 1-12 mg weekly |
Activates three receptor systems (GIP, GLP-1, glucagon) for maximum metabolic effects.
Triple agonist targeting GIP, GLP-1, and glucagon receptors. Showing unprecedented weight loss in clinical trials.
Activates three receptor systems (GIP, GLP-1, glucagon) for maximum metabolic effects.
Retatrutide is at the following stage in the published literature: Phase 3 trials. All information is for research and educational purposes only.
Reported half-life: ~6 days.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.